Commercializing any type of product requires a degree of process reinvention, but the unique demands of advanced therapies have presented challenges not seen in biopharmaceuticals. As innovation continues to propel cell and gene therapies towards a promising future, the industry faces pivotal questions regarding how to adapt well-established, long-term follow-up strategies to this intricate and transformative treatment paradigm.
It's crucial to articulate evidence-based value proposition from the outset, starting from clinical trials, to effectively communicate the proven potential that extends throughout the entire value chain. While we have witnessed digital capabilities navigating the pharma through evolving landscape, the question in the realm of CGT remains - how much closer are we to demonstrating value using the universal language of data?
In this webinar, senior leaders from Bayer, Sumitomo, Mustang Bio and Microvascular Therapeutics will share their visions on key trends shaping the future of CGT clinical development, revealing how they adopt a long-term perspective and analyze data strategies to achieve commercial excellence.
Key takeaways from this one-hour session include:
• Data and Automation: Scale up digital capability to close the experience gap from R&D to manufacturing
• Infuse patient-centricity into every stakeholder journey and delivering continuous patient support to generate comprehensive RWE
• Leverage long-term follow up data to translate the unique values of CGT
Sign up today to participate in the discussion and ask questions of our expert panel or listen on-demand.
Â
This webinar is run in conjunction with the Reuters Events: Pharma USA 2024 event in Philadelphia (March 26-27). Check out our Cell & Gene Therapy stage for more information.
